All In Biotech

Drug Trial Radar · NCT06625320

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

500

Actual

Start

Oct 16, 2024

Primary completion

Jun 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Conditions

  • Pancreatic Cancer
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

  • RMC-6236Drug

    Oral Tablets

  • GemcitabineDrug

    intravenous (IV) infusion

  • nab-paclitaxelDrug

    IV infusion

  • IrinotecanDrug

    IV infusion

  • Liposomal irinotecanDrug

    IV infusion

  • 5-fluorouracilDrug

    IV infusion

  • leucovorinDrug

    IV infusion

  • OxaliplatinDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) in the RAS G12-mutant populationTime frame: Up to approximately 3 years
  2. Overall survival (OS) in the RAS G12-mutant populationTime frame: Up to approximately 3 years

Locations

60 sites in 7 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic Cancer Center - Phoenix

    Phoenix, Arizona

  • City of Hope-Duarte

    Duarte, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • UC San Diego Health Moores Cancer Center

    San Diego, California

  • Mission Hall UCSF

    San Francisco, California

  • Rocky Mountain Cancer

    Aurora, Colorado

  • Mayo Clinic Cancer Center - Florida

    Jacksonville, Florida

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Cancer Care Centers of Brevard Inc

    Palm Bay, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • The Queen's Medical Center

    Honolulu, Hawaii

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Johns Hopkins

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic Cancer Center - Rochester

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • NYU Lagone Health

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • Abramson Cancer Center Clinical Research Unit

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute (Tennessee)

    Nashville, Tennessee

  • Texas Oncology Sammons

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - Central South

    Irving, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Institut Paoli Calmettes

    Marseille, France

  • Centre Eugene Marquis

    Rennes, France

  • Hopital Paul Brousse

    Villejuif, France

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.